Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Lodz, Poland.
Int J Mol Sci. 2021 Aug 26;22(17):9264. doi: 10.3390/ijms22179264.
The development in the area of novel anticancer prodrugs (conjugates and complexes) has attracted growing attention from many research groups. The dangerous side effects of currently used anticancer drugs, including cisplatin and other platinum based drugs, as well their systemic toxicity is a driving force for intensive search and presents a safer way in delivery platform of active molecules. Silicon based nanocarriers play an important role in achieving the goal of synthesis of the more effective prodrugs. It is worth to underline that silicon based platform including silica and silsesquioxane nanocarriers offers higher stability, biocompatibility of such the materials and pro-longed release of active platinum drugs. Silicon nanomaterials themselves are well-known for improving drug delivery, being themselves non-toxic, and versatile, and tailored surface chemistry. This review summarizes the current state-of-the-art within constructs of silicon-containing nano-carriers conjugated and complexed with platinum based drugs. Contrary to a number of other reviews, it stresses the role of nano-chemistry as a primary tool in the development of novel prodrugs.
新型抗癌前药（缀合物和配合物）领域的发展引起了许多研究小组的越来越多的关注。目前使用的抗癌药物（包括顺铂和其他铂类药物）以及其全身毒性的危险副作用是积极寻找更安全的方法的驱动力，为活性分子的输送平台提供了更安全的方法。基于硅的纳米载体在实现更有效的前药合成的目标中发挥着重要作用。值得强调的是，基于硅的平台，包括二氧化硅和硅倍半氧烷纳米载体，提供了更高的稳定性、这种材料的生物相容性和活性铂药物的延长释放。硅纳米材料本身因其改善药物传递、本身无毒、多功能和定制的表面化学而闻名。这篇综述总结了目前与含硅纳米载体缀合和与铂类药物络合的构建体的最新进展。与许多其他综述不同，它强调了纳米化学作为开发新型前药的主要工具的作用。
